Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)
Close on Nov 17, 2026Market cap $1.78BP/E –Yield –
Agios Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Agios Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -418.2%. For fiscal 2025 it was -764.0%, against 1845.9% the year before. The highest annual figure on record is 1845.9% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -764.0% | −2609.9 |
| FY2024 | Dec 31, 2024 | 1845.9% | +3158.6 |
| FY2023 | Dec 31, 2023 | -1312.6% | +315.2 |
| FY2022 | Dec 31, 2022 | -1627.8% | −1278.9 |
| FY2019 | Dec 31, 2019 | -349.0% | +17.6 |
| FY2018 | Dec 31, 2018 | -366.6% | +365.0 |
| FY2017 | Dec 31, 2017 | -731.6% | −447.6 |
| FY2016 | Dec 31, 2016 | -284.0% | −84.8 |
| FY2015 | Dec 31, 2015 | -199.1% | −117.3 |
| FY2014 | Dec 31, 2014 | -81.9% | +72.4 |
| FY2013 | Dec 31, 2013 | -154.2% | −74.2 |
| FY2012 | Dec 31, 2012 | -80.1% | +28.5 |
| FY2011 | Dec 31, 2011 | -108.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -225.1% | +674.3 |
| Q1 FY2026 | Mar 31, 2026 | -477.7% | +545.5 |
| Q4 FY2025 | Dec 31, 2025 | -541.1% | +358.5 |
| Q3 FY2025 | Sep 30, 2025 | -803.1% | −11377.7 |
| Q2 FY2025 | Jun 30, 2025 | -899.4% | +216.3 |
| Q1 FY2025 | Mar 31, 2025 | -1023.3% | −27.4 |
| Q4 FY2024 | Dec 31, 2024 | -899.6% | +451.1 |
| Q3 FY2024 | Sep 30, 2024 | 10574.7% | +11809.0 |
| Q2 FY2024 | Jun 30, 2024 | -1115.7% | +132.9 |
| Q1 FY2024 | Mar 31, 2024 | -995.8% | +448.6 |
| Q4 FY2023 | Dec 31, 2023 | -1350.7% | −2198.2 |
| Q3 FY2023 | Sep 30, 2023 | -1234.3% | +1090.7 |
| Q2 FY2023 | Jun 30, 2023 | -1248.6% | +396.1 |
| Q1 FY2023 | Mar 31, 2023 | -1444.4% | +9946.7 |
| Q4 FY2022 | Dec 31, 2022 | 847.5% | +1069.2 |
| Q3 FY2022 | Sep 30, 2022 | -2325.0% | −2039.8 |
| Q2 FY2022 | Jun 30, 2022 | -1644.7% | −1402.4 |
| Q1 FY2022 | Mar 31, 2022 | -11391.1% | −11344.9 |
| Q4 FY2020 | Dec 31, 2020 | -221.7% | +67.1 |
| Q3 FY2020 | Sep 30, 2020 | -285.2% | +122.8 |
| Q2 FY2020 | Jun 30, 2020 | -242.3% | +176.8 |
| Q1 FY2020 | Mar 31, 2020 | -46.2% | +261.7 |
| Q4 FY2019 | Dec 31, 2019 | -288.8% | +17.0 |
| Q3 FY2019 | Sep 30, 2019 | -408.0% | +214.9 |
| Q2 FY2019 | Jun 30, 2019 | -419.0% | −248.9 |
| Q1 FY2019 | Mar 31, 2019 | -307.9% | +728.6 |
| Q4 FY2018 | Dec 31, 2018 | -305.8% | +595.1 |
| Q3 FY2018 | Sep 30, 2018 | -622.9% | +56.3 |
| Q2 FY2018 | Jun 30, 2018 | -170.1% | +562.2 |
| Q1 FY2018 | Mar 31, 2018 | -1036.6% | −406.9 |
| Q4 FY2017 | Dec 31, 2017 | -901.0% | −798.5 |
| Q3 FY2017 | Sep 30, 2017 | -679.1% | +20.2 |
| Q2 FY2017 | Jun 30, 2017 | -732.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -629.7% | – |
| Q4 FY2016 | Dec 31, 2016 | -102.4% | – |
| Q3 FY2016 | Sep 30, 2016 | -699.3% | – |
See a number that looks wrong?